The estimated Net Worth of Ventures Iv, L.P.5 Am Co In... is at least $19.8 Миллион dollars as of 21 June 2019. Ventures In owns over 250,000 units of Crinetics Pharmaceuticals Inc stock worth over $4,794,372 and over the last 6 years Ventures sold CRNX stock worth over $15,040,753.
Ventures has made over 4 trades of the Crinetics Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Ventures sold 250,000 units of CRNX stock worth $5,550,000 on 21 June 2019.
The largest trade Ventures's ever made was selling 262,153 units of Crinetics Pharmaceuticals Inc stock on 22 January 2019 worth over $5,735,908. On average, Ventures trades about 156,398 units every 67 days since 2018. As of 21 June 2019 Ventures still owns at least 94,489 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Ventures In stock trades at the bottom of the page.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen и Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: